hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature

American Journal of Surgical Pathology

Volumn 32, Issue 2, 2008, Pages 205-209

  Lapointe, Jacques ^a,b   Malhotra, Sameer ^b   Higgins, John P ^a   Bair, Eric ^b   Thompson, Maxwell ^a   Salari, Keyan ^a,b   Giacomini, Craig P ^a   Ferrari, Michelle ^b   Montgomery, Kelli ^a   Tibshirani, Robert ^b   Van De Rijn, Matt ^a   Brooks, James D ^b   Pollack, Jonathan R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Androgen signature; Expression profiling; Molecular subtypes; Prognostic markers; Prostate cancer

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN AZGP1; PROTEIN HCAP D3; RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ADENOSINE TRIPHOSPHATASES; ANDROGENS; CARRIER PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IN SITU HYBRIDIZATION; MALE; MULTIPROTEIN COMPLEXES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA, NEOPLASM; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 38649087064     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318124a865     Document Type: Article

References (18)

1. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:995-1000.
2. DePrimo SE, Diehn M, Nelson JB, et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002;3:RESEARCH0032.
3. Descazeaud A, de la Taille A, Allory Y, et al. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate. 2006;66:1037-1043.
4. Hendriksen PJ, Dits NF, Kokame K, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006;66:5012-5020.
5. Henshall SM, Horvath LG, Quinn DI, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006;98:1420-1424.
6. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
7. Kim YH, Girard L, Giacomini CP, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene. 2006;25:130-138.
8. Kittler R, Putz G, Pelletier L, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature. 2004;432:1036-1040.
9. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24:46-50.
10. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 2004;101:811-816.
11. Nomura N, Nagase T, Miyajima N, et al. Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1994;1:223-229.
12. Ono T, Losada A, Hirano M, et al. Differential contributions of condensin I and condensin II to mitotic chromosome architecture in vertebrate cells. Cell. 2003;115:109-121.
13. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
14. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
15. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545-15550.
16. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41-51.
17. Warlick C, Trock BJ, Landis P, et al. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006;98:355-357.
18. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107-113.